°­¿µÁØ ¸íÀÇ

Á¤È®ÇÑ Áø´Ü°ú ¼¶¼¼ÇÑ ¼ö¼úÀÇ À¯¹æ¾Ï Àü¹®°¡

°­¿µÁØ ¸íÀÇ

  • ¼Ò ¼Ó
    °¡Å縯´ëÀÎõ¼º¸ðº´¿ø
  • Áø·á°ú
    À¯¹æ¿Ü°ú
  • Àü¹®ºÐ¾ß
    À¯¹æÁúȯ, À¯¹æ¾Ï

°­¿µÁØ ±³¼ö´Â À¯¹æ¾ÏÀ» Àü¹®À¸·Î Áø·áÇÏ´Â À¯¹æ¿Ü°ú ÀÇ»ç´Ù. ¼­¿ï´ëÇб³º´¿ø À¯¹æ³»ºÐºñ¿Ü°ú¿¡¼­ ÀÓ»ó°­»ç¿Í Áø·á±³¼ö¸¦ ¿ªÀÓÇß°í, UAE¿Õ¸³º´¿ø¿¡¼­ ±³¼ö·Î ÀçÁ÷Çß´Ù. ÇöÀç °¡Å縯´ë ÀÎõ¼º¸ðº´¿ø¿¡¼­ Áø´Ü°ú ¼ö¼ú, Ç×¾ÏÄ¡·á, Ä¡·á ÈÄ ÃßÀû°ü¸®±îÁö Àü °úÁ¤À» Á÷Á¢ ¸ÃµÇ, ÇÊ¿äÇÑ °æ¿ì Á¾¾ç³»°ú¸¦ ºñ·ÔÇÑ ¿©·¯ Áø·á°ú¿Í Àû±ØÀûÀ¸·Î Çù·ÂÇØ ȯÀÚ¿¡°Ô ÃÖ¼±ÀÇ Ä¡·á¸¦ Á¦°øÇÑ´Ù. ¼ö¼ú¿¡¼­´Â ·Îº¿À» ÀÌ¿ëÇÑ ÃÖ¼Òħ½À ¼ö¼ú·Î ÈäÅÍ¿Í ½Åü ºÎ´ãÀ» ÁÙÀ̰í, Á¾¾ç¼ºÇü ±â¹ýÀ¸·Î ¾ÏÀ» ¾ÈÀüÇÏ°Ô Á¦°ÅÇϸ鼭 À¯¹æÀÇ ¸ð¾çÀ» ÇÔ²² º¹¿øÇÑ´Ù. ¶ÇÇÑ ÀΰøÁö´ÉÀ» Ȱ¿ëÇÑ ¸ÂÃã Ä¡·á¸¦ ¿¬±¸ÇØ Áø·á¿¡ Àû¿ëÇϰí ÀÖ´Ù. Çѱ¹À¯¹æ¾ÏÇÐȸÀÇ ¿©·¯ À§¿øÈ¸¿Í ·Îº¿¡¤³»½Ã°æ ÃÖ¼Òħ½À ¹× Á¾¾ç¼ºÇü À¯¹æ¼ö¼ú ¿¬±¸È¸ µî¿¡¼­ Ȱµ¿ÇÏ¸ç ´ëÇѿܰúÇÐȸ »êÇÏ AIÀ§¿øÈ¸¿¡¼­ À¯¹æÀ§¿øÀ¸·Î Ȱµ¿ÇÑ´Ù. Ãֽмö¼ú, Ä¡·á¹ýÀ» Áø·á¿¡ ¹Ý¿µÇϱâ À§ÇØ ³ë·ÂÇÑ´Ù. Áø´ÜÀÇ Á¤È®¼º°ú ȯÀÚ¿ÍÀÇ ¼ÒÅëÀ» Áß¿äÇÏ°Ô ¿©±â¸ç, ÀÎõ Áö¿ª¿¡¼­ ½Å·ÚÇÒ ¼ö ÀÖ´Â À¯¹æ¾Ï Ä¡·á¸¦ Á¦°øÇÑ´Ù.

¸íÀÇÇÁ·ÎÇÊ ¸íÀÇ ÇÁ·ÎÇÊ

ÇзÂ

Educational Background
  • µ¿±¹´ë ÀÇ´ë ¹Ú»ç
  • µ¿±¹´ë ÀÇ´ë ¼®»ç
  • µ¿±¹´ë ÀÇ´ë Çлç

ÁÖ¿ä°æ·Â

Work Experience
  • úÞ) °¡Å縯´ë ÀÎõ¼º¸ðº´¿ø À¯¹æ°©»ó¼±¿Ü°ú ºÎ±³¼ö
  • ÀÎõ±¤¿ª½ÃÀÇ·á¿ø ¿Ü°ú°úÀå (2018)
  • ¼­¿ï´ëÇб³º´¿ø Áø·á±³¼ö (2017)
  • Sheikh Khalifa Specialty Hospital, Consultant (¾Æ¶ø¿¡¹Ì·¹ÀÌÆ® ¿Õ¸³º´¿ø, ±³¼ö) (2016)

¼ö»ó³»¿ª

Awards List
  • Best Poster, 39th Congress of the European Society of Surgical Oncology (2019)
  • Good Poster Award, Global Breast Cancer Conference 2016 (2016)

ÇÐȸȰµ¿

Academic activities
  • Çѱ¹À¯¹æ¾ÏÇÐȸ ÆíÁýÀ§¿øÈ¸ °£»ç µî ÇÐȸ ³» ´Ù¼ö À§¿ø
  • Çѱ¹ ·Îº¿-³»½Ã°æ ÃÖ¼Òħ½À À¯¹æ ¼ö¼ú ¿¬±¸È¸ (KoREa-BSG)
  • ´ëÇѿܰúÇÐȸ »êÇÏ AIÀ§¿øÈ¸ À¯¹æºÐ°ú À§¿ø
  • ´ëÇѳ»½Ã°æº¹°­°æ¿Ü°úÇÐȸ (KSERS), Çѱ¹¿Ü°ú·Îº¿¼ö¼ú¿¬±¸È¸ (KAROS)
  • Çѱ¹Á¾¾ç¼ºÇüÀ¯¹æ¼ö¼ú ¿¬±¸È¸ (KOPBS) µî ´Ù¼ö
Àú¼­ ¾ÆÀÌÄÜ

ÁýÇÊÀú¼­

ÃÑ 0°Ç
¿¬±¸ ¾ÆÀÌÄÜ

ÁÖ¿ä³í¹®

ÃÑ 7°Ç
Á¦ ¸ñ Multi-modal AI for comprehensive breast cancer prognostication
¹ßÇ¥³âµµ 2026 ¹ßÇ¥Áö Nat Commun.
Á¦ ¸ñ Contributing factors of contralateral breast cancer in patients with BRCA mutation (ON-BRCA II study, KoREa-BSG 11)
¹ßÇ¥³âµµ 2026 ¹ßÇ¥Áö Breast Cancer Res.
Á¦ ¸ñ Risk Stratification for Malignant Upgrade in Breast Atypical Hyperplasia: A Korean Multi-Institutional Analysis from Academic Hospitals
¹ßÇ¥³âµµ 2026 ¹ßÇ¥Áö Korean Journal of Clinical Oncology
Á¦ ¸ñ Large Language Model Versus Manual Review for Clinical Data Curation in Breast Cancer: Retrospective Comparative Study
¹ßÇ¥³âµµ 2025 ¹ßÇ¥Áö JMIR Medical Informatics
Á¦ ¸ñ Factors Associated with Surgical Excision in Patients with Papillary Breast Lesions: A 20-Year Single-Center Experience in South Korea
¹ßÇ¥³âµµ 2024 ¹ßÇ¥Áö J Med Sur Res
Á¦ ¸ñ Prognosis of Patients with Breast Cancer Following Delayed Diagnosis During the COVID-19 Pandemic: A Real-World Cohort Study
¹ßÇ¥³âµµ 2024 ¹ßÇ¥Áö Ann Surg Oncol.
Á¦ ¸ñ Minimal Access vs Conventional Nipple-Sparing Mastectomy
¹ßÇ¥³âµµ 2024 ¹ßÇ¥Áö JAMA Surg.

¸íÀÇqna ¸íÀÇ QnA

Q °¡Àå °ü½É ÀÖ´Â ºÐ¾ß¿Í ¾÷ÀûÀÌ ÀÖ´Ù¸é ¾Ë·ÁÁÖ¼¼¿ä

À¯¹æ¾ÏÀ» ¾ÈÀüÇÏ°Ô Ä¡·áÇϸ鼭 ÈäÅÍ¿Í ½Åü º¯È­¸¦ ÃÖ¼ÒÈ­Çϰí, ȯÀÚÀÇ »îÀÇ ÁúÀ» ³ôÀÌ´Â °ÍÀ» °¡Àå Áß¿äÇÏ°Ô ¿©±ä´Ù. À̸¦ À§ÇØ ·Îº¿¼ö¼ú°ú ÃÖ¼Òħ½À ¼ö¼ú, ÀΰøÁö´ÉÀ» Ȱ¿ëÇÑ ¸ÂÃã Ä¡·á¸¦ ¿¬±¸ÇØ Áö¼ÓÀûÀÎ ³í¹®À» ¾²°í ÀÖÀ¸¸ç Áø·á¿¡ Àû¿ëÇϰí ÀÖ´Ù. ¶ÇÇÑ ´ÙÇÐÁ¦ Çù·Â°ú ÃֽŠġ·á Áö°ßÀÌ È¯ÀÚ Áø·á¿¡ ¹Ý¿µµÇµµ·Ï ¿©·¯ ¹æ¸éÀ¸·Î ³ë·ÂÇϰí ÀÖ´Ù.

Q ȯÀÚ Áø·á¿¡ ÀÖ¾î °¡Àå Áß¿äÇÏ°Ô »ý°¢ÇÏ´Â °¡Ä¡´Â?

Á¤È®ÇÑ Áø´Ü°ú ȯÀÚÀÇ »îÀÇ ÁúÀ» °¡Àå Áß¿äÇÏ°Ô »ý°¢ÇÑ´Ù. °°Àº À¯¹æ¾ÏÀÌ¶óµµ È¯ÀÚ¸¶´Ù »óÅÂ¿Í »óȲÀÌ ´Ù¸£±â ¶§¹®¿¡, °Ë»ç °á°ú¿Í Ä¡·á ¹æ¹ýÀ» ÃæºÐÈ÷ ¼³¸íÇϰí ȯÀÚ°¡ ÀÌÇØÇÑ µÚ ÇÔ²² °áÁ¤Çϵµ·Ï ÇÑ´Ù. ¾ÏÀ» Ä¡·áÇÏ´Â °Í¿¡ ±×Ä¡Áö ¾Ê°í Ä¡·á ÀÌÈÄÀÇ ÀÏ»ó°ú »îÀÇ Áú±îÁö °í·ÁÇÏ´Â °ÍÀ» Áø·áÀÇ ±âÁØÀ¸·Î »ï´Â´Ù.

Q ȯÀڵ鿡°Ô ÀüÇÏ°í ½ÍÀº ¸»¾¸

À¯¹æ¾Ï Áø´ÜÀ» ¹ÞÀ¸¸é ´©±¸³ª µÎ·Æ°í ¸·¸·ÇÕ´Ï´Ù. ÇÏÁö¸¸ À¯¹æ¾ÏÀº Á¶±â¿¡ ¹ß°ßÇØ ÀûÀýÈ÷ Ä¡·áÇÏ¸é °æ°ú°¡ ÁÁÀº ¾ÏÀÔ´Ï´Ù. È¥ÀÚ Å« °áÁ¤À» ³»¸®½Ç ÇÊ¿ä´Â ¾ø½À´Ï´Ù. Áø´ÜºÎÅÍ ¼ö¼ú°ú Ä¡·á, ÀÌÈÄ °ü¸®±îÁö °ç¿¡¼­ ÇÔ²²Çϸç, Ä¡·á È¿°ú¿Í »îÀÇ ÁúÀ» ¸ðµÎ °í·ÁÇÑ ÃÖ¼±ÀÇ ¹æ¹ýÀ» ÇÔ²² ã°Ú½À´Ï´Ù. ±Ã±ÝÇÑ Á¡Àº ¾ðÁ¦µç ÆíÇÏ°Ô ¸»¾¸ÇØ ÁֽʽÿÀ.

¸íÀÇqna ¸íÀÇ ¼Ò¼Óº´¿ø

°¡Å縯´ëÀÎõ¼º¸ðº´¿ø

»ó±ÞÁ¾ÇÕº´¿ø
ÀüÈ­ ¾ÆÀÌÄÜ ´ëÇ¥¹øÈ£
1544-9004
À¥»çÀÌÆ® ¾ÆÀÌÄÜȨÆäÀÌÁö

ÁÖ¿ä½Ã¼³

ÀÀ±Þ½Ç ÀÀ±Þ½Ç
Ŭ¸®´Ð Ŭ¸®´Ð
Á¾ÇÕ°ËÁø¼¾ÅÍ Á¾ÇÕ°ËÁø¼¾ÅÍ
¾Ï¼¾ÅÍ ¾Ï¼¾ÅÍ
ÁÖÂ÷½Ã¼³ ÁÖÂ÷½Ã¼³

1955³â 6¿ù °³¿øÇÑ °¡Å縯´ëÇб³ ÀÎõ¼º¸ðº´¿øÀº ÀÎõ Áö¿ª ÃÖÃÊÀÇ ´ëÇк´¿øÀÌ´Ù. ÀÎõ¼º¸ðº´¿øÀº '±×¸®½ºµµÀÇ »ç¶ûÀÌ »ì¾Æ ¼û ½¬´Â ÃÖ»óÀÇ Ã·´ÜÁø·á'¶ó´Â ¹Ì¼Ç ¾Æ·¡ 2019³â ±âÁØ 835º´»ó ±Ô¸ðÀÇ »ó±ÞÁ¾ÇÕº´¿øÀ¸·Î ¼ºÀåÇß´Ù. ¡®ÇöÁ¸ÇÏ´Â ¸ðµç ³úÁúȯÀ» Á¤º¹ÇÑ´Ù¡¯´Â ¸ñÇ¥·Î ±¹³» óÀ½À¸·Î ¼±º¸ÀÎ ¡®³úº´¿ø¡¯ÀÇ ¼º°øÀûÀÎ °³¿ø°ú ÇÔ²² ²ÞÀÇ ¾Ï Ä¡·á Àåºñ·Î ºÒ¸®´Â ¡®¸Þ¸£µð¾È ¶óÀ̳«(MRIdian LINAC)¡¯À» ±¹³» ÃÖÃÊ·Î µµÀÔÇØ ¾ÏȯÀڵ鿡°Ô Ä¡À¯ÀÇ Èñ¸ÁÀ» ÀüÇϰí ÀÖ´Ù.

°¡Å縯´ëÀÎõ¼º¸ðº´¿ø À̹ÌÁö

ÀÎõ±¤¿ª½Ã ºÎÆò±¸ µ¿¼ö·Î56

Ȩ
³»°¡ ¾Ë°íÀÖ´Â ¸íÀǸ¦ ÃßÃµÇØÁÖ¼¼¿ä